ConductScience.org, home

Paper40940319

LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer.

Chen S and 5 others. Int J Oral Sci, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer. Papers, record 40940319. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40940319

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer.
PubMed
Journal
Int J Oral Sci
PubMed
Year
2025
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-06-19
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chen SShengkaihttps://orcid.org/0000-0003-2283-8341
2Dai ZZhenlinhttps://orcid.org/0000-0003-4993-5192
3Shi JJianbo
4Rui MMengyu
5Zhang ZZhiyuan
6Xu QQinhttps://orcid.org/0000-0003-3524-2256

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ErbB ReceptorsMajor topic
Mouth NeoplasmsMajor topic
RNA, Long NoncodingMajor topic
Drug Resistance, NeoplasmMajor topic
Humans
Cell Line, Tumor
Phosphorylation
Signal Transduction
STAT3 Transcription Factor
Cell Hypoxia
Autophagy
Proto-Oncogene Proteins c-cbl

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82273095, 82203614National Natural Science Foundation of China (National Science Foundation of China)PubMed
82203614National Natural Science Foundation of China (National Science Foundation of China)PubMed

Source PubMed

Download CSV of grants

References59

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131639425EGFR-mediated autophagy in tumourigenesis and therapeutic resistance.Cancer Lett2020https://conductscience.org/library/papers/31639425PubMed
221171968Inhibiting adenoid cystic carcinoma cells growth and metastasis by blocking the expression of ADAM 10 using RNA interference.J Transl Med2010https://conductscience.org/library/papers/21171968PubMed
322411794Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1.Proc Natl Acad Sci U S A2012https://conductscience.org/library/papers/22411794PubMed
424590058STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious.Cancer Res2014https://conductscience.org/library/papers/24590058PubMed
526282175Ligand-Independent EGFR Signaling.Cancer Res2015https://conductscience.org/library/papers/26282175PubMed
627163161A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: Hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathway.Autophagy2016https://conductscience.org/library/papers/27163161PubMed
712829707Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination.J Biol Chem2003https://conductscience.org/library/papers/12829707PubMed
819692680Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med2009https://conductscience.org/library/papers/19692680PubMed
917189395Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.Clin Cancer Res2006https://conductscience.org/library/papers/17189395PubMed
1021262846Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2.Proc Natl Acad Sci U S A2011https://conductscience.org/library/papers/21262846PubMed
1118694561Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation.Dev Cell2008https://conductscience.org/library/papers/18694561PubMed
1212717448Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation.Nat Cell Biol2003https://conductscience.org/library/papers/12717448PubMed
1316763281Epidermal growth factor receptor biology in head and neck cancer.J Clin Oncol2006https://conductscience.org/library/papers/16763281PubMed
1425503978Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks.Nat Commun2014https://conductscience.org/library/papers/25503978PubMed
1538499147Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.J Thorac Oncol2024https://conductscience.org/library/papers/38499147PubMed
1621376230Hallmarks of cancer: the next generation.Cell2011https://conductscience.org/library/papers/21376230PubMed
1720965422Autophagy and the integrated stress response.Mol Cell2010https://conductscience.org/library/papers/20965422PubMed
1819417138The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.Cancer Res2009https://conductscience.org/library/papers/19417138PubMed
1919229244Role of BNIP3 and NIX in cell death, autophagy, and mitophagy.Cell Death Differ2009https://conductscience.org/library/papers/19229244PubMed
2017218988Targeting TACE-dependent EGFR ligand shedding in breast cancer.J Clin Invest2007https://conductscience.org/library/papers/17218988PubMed

See all 59 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42943257Mechanisms and Therapeutic Advances of Natural Products Regulating Non-Coding RNAs in Cancer.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42943257PubMed
41760308Physalin A Suppresses Human Oral Squamous Carcinoma Cell Migration and Invasion Through Inhibiting Grb2/Ras and MMP/uPA Signaling Pathways.In Vivo2026https://conductscience.org/library/papers/41760308PubMed

Download CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BNIP3664PubTator's text mininghttps://conductscience.org/library/genes/664NCBI Gene
CBL867PubTator's text mininghttps://conductscience.org/library/genes/867NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
GRB22885PubTator's text mininghttps://conductscience.org/library/genes/2885NCBI Gene
HIF1A3091PubTator's text mininghttps://conductscience.org/library/genes/3091NCBI Gene
STAT36774PubTator's text mininghttps://conductscience.org/library/genes/6774NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40940319

GET https://conductscience.org/api/papers/v1/40940319/references?page=2